Loading
Leads the German Hodgkin Study Group and HD21, which made BrECADD the most effective and least toxic regimen for advanced Hodgkin lymphoma.
Peter Borchmann chairs the German Hodgkin Study Group and was principal investigator of HD21, which showed the brentuximab-based BrECADD regimen is both more effective and less toxic than escalated BEACOPP in advanced-stage Hodgkin lymphoma with 95% three-year progression-free survival, and of HD18, which used PET to reduce treatment from six cycles to four. He leads GHSG trials of immunotherapy in first-line disease.
Radiotherapy cannot be omitted in early-stage favourable Hodgkin lymphoma on the basis of a negative interim scan without a clinically relevant loss of tumour control. The scan is better at identifying who needs more than at identifying who needs less.
The basis for four cycles of escalated BEACOPP as the German standard when the interim scan is negative, and the reason rituximab was abandoned as an addition to that regimen. The authors recommend the scan-guided strategy for all patients with advanced-stage disease.
Shares Uniklinik Köln (CIO), German Hodgkin Study Group, GHSG HD10, Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group and the tags hodgkin, ghsg.
Shares GHSG HD10, Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group, GHSG HD16, PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Shares Brentuximab vedotin, Hodgkin lymphoma, Antibody-drug conjugate (ADC) and the tag hodgkin.
Shares GHSG HD21, PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group, Brentuximab vedotin, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting.
Shares GHSG HD10, Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Hodgkin lymphoma.
Shares Brentuximab vedotin, Hodgkin lymphoma, Antibody-drug conjugate (ADC) and the tag hodgkin.
Shares Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group, GHSG HD16, PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group, GHSG HD18.
Shares Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group, GHSG HD16, Brentuximab vedotin, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting.